Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM; Polymer Alternative for CDI Treatment (PACT) investigators.

Clin Infect Dis. 2014 Aug 1;59(3):345-54. doi: 10.1093/cid/ciu313. Epub 2014 May 5.

PMID:
24799326
2.

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.

McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, Wagener G, Chasan-Taber S.

PLoS One. 2012;7(11):e49006. doi: 10.1371/journal.pone.0049006. Epub 2012 Nov 13.

3.

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST.

Lancet. 2010 Mar 20;375(9719):998-1006. doi: 10.1016/S0140-6736(10)60284-X.

PMID:
20227758
4.

A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.

Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S.

Am J Kidney Dis. 2010 Feb;55(2):307-15. doi: 10.1053/j.ajkd.2009.10.051. Epub 2009 Dec 30.

PMID:
20042256
5.

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.

Nephrol Dial Transplant. 2009 Jan;24(1):278-85. doi: 10.1093/ndt/gfn488. Epub 2008 Sep 27.

PMID:
18820280
6.

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1125-30. doi: 10.2215/CJN.05161107. Epub 2008 May 1.

7.

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.

Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ.

Clin Nephrol. 2007 Dec;68(6):386-91.

PMID:
18184521
8.

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.

Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK.

Kidney Int. 2007 Nov;72(9):1130-7. Epub 2007 Aug 29.

9.

Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, Weiss K, Simon S, John JF Jr, Garber G, Chasan-Taber S, Davidson DM; Tolevamer Study Investigator Group.

Clin Infect Dis. 2006 Aug 15;43(4):411-20. Epub 2006 Jul 11.

PMID:
16838228
10.

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P.

Am Heart J. 2005 May;149(5):820-5.

PMID:
15894962
11.

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.

Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM.

J Bone Miner Res. 2005 May;20(5):764-72. Epub 2004 Dec 20.

12.

Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.

Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM.

Arthritis Rheum. 2005 Jan;52(1):290-5.

13.

Determinants of progressive vascular calcification in haemodialysis patients.

Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK.

Nephrol Dial Transplant. 2004 Jun;19(6):1489-96. Epub 2004 Apr 21.

PMID:
15102961
14.

Validity and reproducibility of a physical activity questionnaire in women.

Chasan-Taber L, Erickson JB, Nasca PC, Chasan-Taber S, Freedson PS.

Med Sci Sports Exerc. 2002 Jun;34(6):987-92.

PMID:
12048326
15.

Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?

Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM.

J Am Coll Cardiol. 2002 Feb 20;39(4):695-701.

16.

Reproducibility of a self-administered lifetime physical activity questionnaire among female college alumnae.

Chasan-Taber L, Erickson JB, McBride JW, Nasca PC, Chasan-Taber S, Freedson PS.

Am J Epidemiol. 2002 Feb 1;155(3):282-9.

PMID:
11821254
17.

Quality of care by race and gender for congestive heart failure and pneumonia.

Ayanian JZ, Weissman JS, Chasan-Taber S, Epstein AM.

Med Care. 1999 Dec;37(12):1260-9.

PMID:
10599607
18.

Hospital readmissions and quality of care.

Weissman JS, Ayanian JZ, Chasan-Taber S, Sherwood MJ, Roth C, Epstein AM.

Med Care. 1999 May;37(5):490-501.

PMID:
10335751
19.

Quality of care for two common illnesses in teaching and nonteaching hospitals.

Ayanian JZ, Weissman JS, Chasan-Taber S, Epstein AM.

Health Aff (Millwood). 1998 Nov-Dec;17(6):194-205.

PMID:
9916369
20.

Different psychological status in the two hemispheres of two split-brain patients.

Schiffer F, Zaidel E, Bogen J, Chasan-Taber S.

Neuropsychiatry Neuropsychol Behav Neurol. 1998 Jul;11(3):151-6.

PMID:
9742514

Supplemental Content

Loading ...
Support Center